Targeted therapies for cancer

Zhou, Zhijun; Li, Min

doi:10.1186/s12916-022-02287-3

Cited by 75 publications

(34 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although emerging therapies and various targeted drugs are developed for cancer treatment, cancer cannot be cured entirely. Therefore, there is an urgent need to discover early diagnostic tools, predictive biomarkers, and more reliable treatments to improve cancer patients' cure and survival rates [6][7][8][9][10]. The significance of pan-cancer research is to apply diagnosis and treatment to more cancers through cross-cancer similarity [11,12].…”

Section: Introductionmentioning

confidence: 99%

Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer

Shen

Peng

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

CDCA3 is an essential regulator in cell mitosis and can regulate many physiological and pathological processes in the human body by stimulating certain proteins such as cell cycle regulatory proteins, transcription factors, and signal transduction molecules. Although several studies have shown that dysregulation of CDCA3 is a common phenomenon in human cancers, no systematic pan-cancer analysis has been performed. In this study, we comprehensively investigated the role of CDCA3 in 33 human cancer types by utilizing multiple cancer-related databases and bioinformatics analysis tools, including TCGA, GTEx, GEPIA, TIMER, STRING, Metascape, and Cytoscape. Evidence from bioinformatics databases shows that CDCA3 is overexpressed in almost all human cancer types, and its overexpression is significantly associated with survival in patients with more than ten cancer types. CDCA3 expression positively correlates with immune cell infiltration levels in multiple human cancer types. Furthermore, the results of the GSEA analysis revealed that overexpression of CDCA3 may promote the malignant progression of cancer by activating various oncogenic signaling pathways in human cancers. In conclusion, our pan-cancer analysis provides a comprehensive overview of the oncogenic role of CDCA3 in multiple human cancer types, suggesting that CDCA3 may serve as a potential therapeutic target and prognostic biomarker in multiple human cancer types.

show abstract

Section: Introductionmentioning

confidence: 99%

Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer

Shen

Peng

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Thus, this therapy affects the cancer cells more than the normal ones. The specific action of targeted therapy differs from traditional chemotherapy, which affects all fast-growing cells [ 160 ]. There are two main types of targeted therapy.…”

Section: Therapeutic Perspectives On Biosensors and Biomarkers In Can...mentioning

confidence: 99%

Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation

Iqbal¹,

Javed

Herrera‐Bravo

et al. 2022

Cancer Cell Int

View full text Add to dashboard Cite

Recent technological advances in nanoscience and material designing have led to the development of point-of-care devices for biomolecule sensing and cancer diagnosis. In situ and portable sensing devices for bedside, diagnosis can effectively improve the patient’s clinical outcomes and reduce the mortality rate. Detection of exosomal RNAs by immuno-biochip with increased sensitivity and specificity to diagnose cancer has raised the understanding of the tumor microenvironment and many other technology-based biosensing devices hold great promise for clinical innovations to conquer the unbeatable fort of cancer metastasis. Electrochemical biosensors are the most sensitive category of biomolecule detection sensors with significantly low concentrations down to the atomic level. In this sense, this review addresses the recent advances in cancer detection and diagnosis by developing significant biological sensing devices that are believed to have better sensing potential than existing facilities.

show abstract

“…Commonly used drugs include targeting vascular endothelial growth factor (VEGF) to inhibit angiogenesis (bevacizumab, ramucirumab and ziv-atriptanib) and drugs inhibiting the epidermal growth factor receptor (EGFR) signalling pathway (cetuximab and panitumumab). Patients receiving matched targeted therapy showed significantly improved overall survival (OS) and progression-free survival (PFS) [118]. However, targeting also has significant side effects, such as allergic reactions, skin toxicity, gastrointestinal toxicity, cardiotoxicity, pulmonary toxicity, etc.…”

Section: Natural Compounds Combined With Targeted Therapymentioning

confidence: 99%

“…Ryegrass seeds contain the bioactive component thymoquinone (TQ). By reducing inflammation and oxidative stress [122], it has anticancer and chemical sensitization properties [118]. The anticancer properties of TQ include promoting apoptosis, cell cycle arrest and ROS production.…”

Section: Natural Compounds Combined With Targeted Therapymentioning

confidence: 99%

The Synergism of Natural Compounds and Conventional Therapeutics against Colorectal Cancer Progression and Metastasis

Liang¹,

Xie²,

Shen³

et al. 2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Cancer progression and metastases are the leading causes of poor outcomes in patients with colon cancer. Colon cancer metastasis is a multigene, multistep, multistage complex process in which target genes, microRNAs, epithelial-stromal transformation, tumour stem cells, the tumour microenvironment, and various cell signalling pathways are implicated in the progression and metastasis of colon cancer. Although conventional therapies have made significant advances in treating the progression and metastasis of colorectal cancer, they have failed to improve survival outcomes. Natural compounds may have more significant potential in preventing and treating colon cancer. Active natural compounds exert their antitumor effects by inducing tumour cell differentiation, promoting tumour cell apoptosis, inhibiting tumour vascular growth, and regulating immunity. Natural compounds, combined with conventional therapies, can target mutant genes and various cellular signalling pathways, inhibit epithelial-stromal transformation, and improve the tumour microenvironment to inhibit tumour progression and metastasis. The synergism of natural compounds and conventional therapeutics has the potential to become a promising therapy for treating colorectal cancer progression and metastases.

show abstract

Targeted therapies for cancer

Cited by 75 publications

References 9 publications

Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer

Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer

Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation

The Synergism of Natural Compounds and Conventional Therapeutics against Colorectal Cancer Progression and Metastasis

Contact Info

Product

Resources

About